Study includes multiple variant vaccines.
New arm of NIAID-sponsored mix-and-match trial will look at Novavax protein vaccine.
NIAID-sponsored study includes Seattle in test for benefits of mixing different vaccine types.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
In a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.